EP1852121A3
(en)
|
1994-08-29 |
2007-11-21 |
Wake Forest University |
Lipid analogs for treating viral infections
|
US7135584B2
(en)
|
1995-08-07 |
2006-11-14 |
Wake Forest University |
Lipid analogs for treating viral infections
|
UA66767C2
(uk)
*
|
1996-10-18 |
2004-06-15 |
Вертекс Фармасьютикалс Інкорпорейтед |
Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
|
GB9707659D0
(en)
*
|
1997-04-16 |
1997-06-04 |
Peptide Therapeutics Ltd |
Hepatitis C NS3 Protease inhibitors
|
DK1003775T3
(da)
*
|
1997-08-11 |
2005-05-30 |
Boehringer Ingelheim Ca Ltd |
Hepatitis C-inhibitorpeptider
|
US6143715A
(en)
*
|
1997-08-11 |
2000-11-07 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C inhibitor peptide analogues
|
US6767991B1
(en)
|
1997-08-11 |
2004-07-27 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C inhibitor peptides
|
GB9806815D0
(en)
*
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
DK1066247T3
(da)
*
|
1998-03-31 |
2007-04-02 |
Vertex Pharma |
Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease
|
GB9809664D0
(en)
|
1998-05-06 |
1998-07-01 |
Hoffmann La Roche |
a-Ketoamide derivatives
|
GB9812523D0
(en)
|
1998-06-10 |
1998-08-05 |
Angeletti P Ist Richerche Bio |
Peptide inhibitors of hepatitis c virus ns3 protease
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
AR022061A1
(es)
*
|
1998-08-10 |
2002-09-04 |
Boehringer Ingelheim Ca Ltd |
Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
|
WO2000051998A1
(en)
|
1999-03-02 |
2000-09-08 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as reversible inhibitors of cathepsin s
|
UA74546C2
(en)
*
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
AU5920400A
(en)
*
|
1999-07-07 |
2001-01-22 |
Du Pont Pharmaceuticals Company |
Cell-based assay systems for examining hcv ns3 protease activity
|
US7122627B2
(en)
|
1999-07-26 |
2006-10-17 |
Bristol-Myers Squibb Company |
Lactam inhibitors of Hepatitis C virus NS3 protease
|
EP1206449A1
(en)
*
|
1999-07-26 |
2002-05-22 |
Bristol-Myers Squibb Company |
Lactam inhibitors of hepatitis c virus ns3 protease
|
US6420364B1
(en)
|
1999-09-13 |
2002-07-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compound useful as reversible inhibitors of cysteine proteases
|
US7026469B2
(en)
|
2000-10-19 |
2006-04-11 |
Wake Forest University School Of Medicine |
Compositions and methods of double-targeting virus infections and cancer cells
|
EP1252178A1
(en)
*
|
1999-12-03 |
2002-10-30 |
Bristol-Myers Squibb Pharma Company |
Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
|
CA2392028C
(en)
*
|
1999-12-07 |
2009-08-18 |
Theravance, Inc. |
Carbamate derivatives having muscarinic receptor antagonist activity
|
AU2001245356A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Bristol-Myers Squibb Pharma Company |
Inhibitors of hepatitis c virus ns3 protease
|
AU2006202124B2
(en)
*
|
2000-04-03 |
2010-01-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3 Protease
|
ES2240446T3
(es)
|
2000-04-03 |
2005-10-16 |
Vertex Pharma |
Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
|
DE60137207D1
(de)
|
2000-04-05 |
2009-02-12 |
Schering Corp |
Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
|
US6914122B2
(en)
|
2000-04-19 |
2005-07-05 |
Schering Corporation |
Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
|
PE20011350A1
(es)
|
2000-05-19 |
2002-01-15 |
Vertex Pharma |
PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
CA2410579C
(en)
|
2000-05-26 |
2010-04-20 |
Jean-Pierre Sommadossi |
Methods and compositions for treating flaviviruses and pestiviruses
|
US20020007324A1
(en)
*
|
2000-06-09 |
2002-01-17 |
Centner David J. |
System and method for effectively conducting transactions between buyers and suppliers
|
JP4298289B2
(ja)
*
|
2000-07-21 |
2009-07-15 |
シェーリング コーポレイション |
C型肝炎ウイルスのns3−セリンプロテアーゼ阻害剤としての新規ペプチド
|
AR034127A1
(es)
*
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
US7244721B2
(en)
*
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
PL365695A1
(en)
*
|
2000-07-21 |
2005-01-10 |
|
Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
AU2002218133A1
(en)
*
|
2000-10-12 |
2002-04-22 |
Viromics Gmbh |
Agents for the treatment of viral infections
|
AU2874902A
(en)
|
2000-10-18 |
2002-04-29 |
Pharmasset Ltd |
Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
|
US7309696B2
(en)
|
2000-10-19 |
2007-12-18 |
Wake Forest University |
Compositions and methods for targeting cancer cells
|
US6846806B2
(en)
|
2000-10-23 |
2005-01-25 |
Bristol-Myers Squibb Company |
Peptide inhibitors of Hepatitis C virus NS3 protein
|
AU2002236591B2
(en)
*
|
2000-12-12 |
2005-07-14 |
Schering Corporation |
Diaryl peptides as NS3-serine protease inhibitors of hepatits C virus
|
WO2002048157A2
(en)
*
|
2000-12-13 |
2002-06-20 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
|
US6653295B2
(en)
|
2000-12-13 |
2003-11-25 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus NS3 protease
|
WO2002057425A2
(en)
|
2001-01-22 |
2002-07-25 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
NZ530000A
(en)
|
2001-07-11 |
2007-03-30 |
Vertex Pharma |
Peptidomimetic bridged bicyclic serine protease inhibitors
|
KR100871648B1
(ko)
|
2001-08-31 |
2008-12-03 |
톰슨 라이센싱 |
조건부 액세스 시스템을 구현하는 방법, 컨텐트를 전송하는 방법 및 그 장치 및 컨텐트를 수신하고 처리하는 방법 및 그 장치
|
AU2002330154A1
(en)
|
2001-09-28 |
2003-04-07 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
MXPA04003825A
(es)
*
|
2001-10-24 |
2004-07-08 |
Vertex Pharma |
Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado.
|
MY151199A
(en)
*
|
2001-11-02 |
2014-04-30 |
Rigel Pharmaceuticals Inc |
Substituted diphenyl heterocycles useful for treating hcv infection
|
WO2003062228A1
(en)
|
2002-01-23 |
2003-07-31 |
Schering Corporation |
Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
JP2005535574A
(ja)
*
|
2002-04-11 |
2005-11-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、特にhcvns3−ns4aプロテアーゼのインヒビター
|
WO2004043339A2
(en)
|
2002-05-20 |
2004-05-27 |
Bristol-Myers Squibb Company |
Substituted cycloalkyl p1' hepatitis c virus inhibitors
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
JP4312711B2
(ja)
|
2002-05-20 |
2009-08-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヘテロ環式スルホンアミドc型肝炎ウイルス阻害剤
|
ATE503764T1
(de)
*
|
2002-05-20 |
2011-04-15 |
Bristol Myers Squibb Co |
Inhibitoren des hepatitis-c-virus
|
AP2005003212A0
(en)
|
2002-06-28 |
2005-03-31 |
Centre Nat Rech Scient |
Modified 2' and 3' nucleoside prodrugs for treating flaviviridae infections.
|
AU2003277891A1
(en)
*
|
2002-09-23 |
2004-04-08 |
Medivir Ab |
Hcv ns-3 serine protease inhibitors
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
BR0316363A
(pt)
|
2002-11-15 |
2005-10-04 |
Idenix Cayman Ltd |
Nucleosìdeos 2'-ramificado e mutação de flaviviridae
|
AU2011203054B2
(en)
*
|
2003-04-11 |
2012-04-26 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
|
WO2004092161A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
CN100453553C
(zh)
*
|
2003-04-11 |
2009-01-21 |
沃泰克斯药物股份有限公司 |
丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
|
WO2004099165A2
(en)
|
2003-05-02 |
2004-11-18 |
Rigel Pharmaceuticals, Inc. |
Heterocyclic compounds and hydro isomers thereof
|
UY28323A1
(es)
|
2003-05-21 |
2004-12-31 |
Boehringer Ingelheim Int |
Compuestos inhibidores de la hepatitis c
|
PT1633766T
(pt)
|
2003-05-30 |
2019-06-04 |
Gilead Pharmasset Llc |
Análogos de nucleósido fluorado modificado
|
CN102020700A
(zh)
*
|
2003-07-18 |
2011-04-20 |
沃泰克斯药物股份有限公司 |
丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
|
PT1658302E
(pt)
|
2003-07-25 |
2010-10-25 |
Centre Nat Rech Scient |
Análogos do nucleósido purina para o tratamento de doenças provocadas por flaviviridae incluindo hepatite c
|
US7576206B2
(en)
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7223745B2
(en)
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
CA2536570A1
(en)
|
2003-08-26 |
2005-03-10 |
Schering Corporation |
Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
|
PE20050374A1
(es)
*
|
2003-09-05 |
2005-05-30 |
Vertex Pharma |
Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
|
JP4685775B2
(ja)
*
|
2003-09-18 |
2011-05-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、とりわけhcvns3−ns4aプロテアーゼの阻害剤
|
KR20060094083A
(ko)
|
2003-09-22 |
2006-08-28 |
베링거 인겔하임 인터내셔날 게엠베하 |
C형 간염 바이러스에 대해 활성인 마크로사이클릭펩타이드
|
RU2006113880A
(ru)
|
2003-09-26 |
2007-11-20 |
Шеринг Корпорейшн (US) |
Макроциклические ингибиторы сериновой протеиназы ns3 вируса гепатита с
|
CN101857631A
(zh)
*
|
2003-10-10 |
2010-10-13 |
沃泰克斯药物股份有限公司 |
丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
|
OA13315A
(en)
|
2003-10-14 |
2007-04-13 |
Intermune Inc |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
|
US8187874B2
(en)
|
2003-10-27 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
KR20060120166A
(ko)
|
2003-10-27 |
2006-11-24 |
버텍스 파마슈티칼스 인코포레이티드 |
Hcv ns3-ns4a 단백질분해효소 저항성 돌연변이
|
EP1944042A1
(en)
|
2003-10-27 |
2008-07-16 |
Vertex Pharmceuticals Incorporated |
Combinations for HCV treatment
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP1689770A1
(en)
|
2003-11-20 |
2006-08-16 |
Schering Corporation |
Depeptidized inhibitors of hepatitis c virus ns3 protease
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
JP4682155B2
(ja)
|
2004-01-21 |
2011-05-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎ウイルスに対して活性な大環状ペプチド
|
BRPI0506945A
(pt)
*
|
2004-01-30 |
2007-06-12 |
Medivir Ab |
inibidores de serina protease ns-3 de hcv
|
CN1938332B
(zh)
*
|
2004-02-04 |
2011-10-19 |
沃泰克斯药物股份有限公司 |
丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
|
SI1719773T1
(sl)
|
2004-02-24 |
2009-08-31 |
Japan Tobacco Inc |
Kondenzirane heterotetraciklične spojine in njihova uporaba kot inhibitorji polimeraze HCV
|
US20070049593A1
(en)
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
TWI393704B
(zh)
|
2004-02-27 |
2013-04-21 |
Merck Sharp & Dohme |
用作c型肝炎病毒ns3絲胺酸蛋白酶抑制劑之硫化合物
|
WO2005085275A1
(en)
|
2004-02-27 |
2005-09-15 |
Schering Corporation |
Inhibitors of hepatitis c virus ns3 protease
|
AU2005222055A1
(en)
|
2004-02-27 |
2005-09-22 |
Schering Corporation |
Compounds as inhibitors of hepatitis C virus NS3 serine protease
|
ATE434621T1
(de)
|
2004-02-27 |
2009-07-15 |
Schering Corp |
Neue verbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
AR048008A1
(es)
*
|
2004-03-12 |
2006-03-15 |
Vertex Pharma |
Procesos para la preparacion de inhibidores de caspasa derivados de los mismos
|
EP1745064B1
(en)
|
2004-04-15 |
2011-01-05 |
Proteolix, Inc. |
Compounds for proteasome enzyme inhibition
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
DK2030981T3
(da)
*
|
2004-05-10 |
2014-10-13 |
Onyx Therapeutics Inc |
Forbindelser til proteasom-enzymhæmning
|
JP2008502718A
(ja)
|
2004-05-20 |
2008-01-31 |
シェーリング コーポレイション |
C型肝炎ウイルスns3セリンプロテアーゼのインヒビターとしての置換型プロリン
|
HRP20110732T1
(hr)
|
2004-07-16 |
2011-11-30 |
Gilead Sciences |
Antivirusni spojevi
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
ES2366478T3
(es)
|
2004-07-20 |
2011-10-20 |
Boehringer Ingelheim International Gmbh |
Análogos peptídicos inhibidores de la hepatitis c.
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
CA2576030A1
(en)
*
|
2004-08-09 |
2006-02-23 |
Alios Biopharma Inc. |
Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
|
US7550559B2
(en)
|
2004-08-27 |
2009-06-23 |
Schering Corporation |
Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
|
CA2580457C
(en)
|
2004-09-14 |
2014-11-04 |
Pharmasset, Inc. |
Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
EP1804821A4
(en)
|
2004-10-01 |
2009-07-15 |
Vertex Pharma |
INHIBITION OF HCV NS3-NS4A PROTEASE
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7468383B2
(en)
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7569600B2
(en)
|
2005-05-13 |
2009-08-04 |
Virochem Pharma Inc. |
Compounds and methods for the treatment of prevention of Flavivirus infections
|
WO2006127289A1
(en)
*
|
2005-05-20 |
2006-11-30 |
Valeant Research & Development |
Treatment of hcv with subtherapeutic doses of ribavirin
|
US20070237818A1
(en)
*
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
JP5160415B2
(ja)
|
2005-06-02 |
2013-03-13 |
メルク・シャープ・アンド・ドーム・コーポレーション |
医薬処方物およびそれを用いる治療方法
|
WO2006130666A2
(en)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Medicaments and methods combining a hcv protease inhibitor and an akr competitor
|
AU2006252519B2
(en)
|
2005-06-02 |
2012-08-30 |
Merck Sharp & Dohme Corp. |
HCV protease inhibitors in combination with food
|
CA2611151A1
(en)
|
2005-06-17 |
2006-12-28 |
Novartis Ag |
Use of sanglifehrin in hcv
|
US7608592B2
(en)
*
|
2005-06-30 |
2009-10-27 |
Virobay, Inc. |
HCV inhibitors
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
NZ565059A
(en)
|
2005-07-25 |
2011-08-26 |
Intermune Inc |
Novel macrocyclic inhibitors of hepatitus C virus replication
|
SI1919898T1
(sl)
|
2005-07-29 |
2011-05-31 |
Tibotec Pharm Ltd |
Makrociklični inhibitorji virusa hepatitisa C
|
CA2617099C
(en)
|
2005-07-29 |
2014-03-25 |
Tibotec Pharmaceuticals Ltd. |
Macrocyclic inhibitors of hepatitis c virus
|
TWI393723B
(zh)
|
2005-07-29 |
2013-04-21 |
Tibotec Pharm Ltd |
C型肝炎病毒之大環抑制劑(九)
|
RU2436787C2
(ru)
|
2005-07-29 |
2011-12-20 |
Тиботек Фармасьютикалз Лтд. |
Макроциклические ингибиторы вируса гепатита с
|
JP5426164B2
(ja)
|
2005-07-29 |
2014-02-26 |
ヤンセン・アールアンドデイ・アイルランド |
C型肝炎ウイルスの大環式インヒビター
|
MY139923A
(en)
|
2005-07-29 |
2009-11-30 |
Tibotec Pharm Ltd |
Macrocylic inhibitors of hepatitis c virus
|
JO2768B1
(en)
|
2005-07-29 |
2014-03-15 |
تيبوتيك فارماسيوتيكالز ليمتد |
Large cyclic inhibitors of hepatitis C virus
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
PE20070210A1
(es)
|
2005-07-29 |
2007-04-16 |
Tibotec Pharm Ltd |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
EP1915382A2
(en)
*
|
2005-08-01 |
2008-04-30 |
Phenomix Corporation |
Hepatitis c serine protease inhibitors and uses therefor
|
KR20080033481A
(ko)
|
2005-08-02 |
2008-04-16 |
버텍스 파마슈티칼스 인코포레이티드 |
세린 프로테아제의 억제제
|
US8399615B2
(en)
|
2005-08-19 |
2013-03-19 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
KR20130110236A
(ko)
*
|
2005-08-19 |
2013-10-08 |
버텍스 파마슈티칼스 인코포레이티드 |
방법 및 중간체
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
BRPI0617274A2
(pt)
|
2005-10-11 |
2011-07-19 |
Intermune Inc |
compostos e métodos para a inibição de replicação viral de hepatite c
|
CA2624166A1
(en)
*
|
2005-10-11 |
2007-04-26 |
Intermune, Inc. |
Inhibitors of viral replication
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP1948678B1
(en)
|
2005-11-09 |
2013-05-01 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
EP2392590A3
(en)
|
2005-11-11 |
2012-03-14 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
EP1966130B1
(en)
*
|
2005-12-23 |
2013-12-11 |
Zealand Pharma A/S |
Modified lysine-mimetic compounds
|
US20090304631A1
(en)
*
|
2006-01-27 |
2009-12-10 |
David Alan Campbell |
Hepatitis c serine protease inhibitors and uses therefor
|
AR059429A1
(es)
*
|
2006-02-09 |
2008-04-09 |
Schering Corp |
Combinaciones que involucran el (los) inhibidor(es) de la protesa hcv y metodos de tratamiento relacionados al (los) mismo (s)
|
EP1991229A2
(en)
|
2006-02-27 |
2008-11-19 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
EP1993994A2
(en)
*
|
2006-03-16 |
2008-11-26 |
Vertex Pharmceuticals Incorporated |
Deuterated hepatitis c protease inhibitors
|
EP2007789B1
(en)
|
2006-04-11 |
2015-05-20 |
Novartis AG |
Spirocyclic HCV/HIV inhibitors and their uses
|
US8017612B2
(en)
|
2006-04-18 |
2011-09-13 |
Japan Tobacco Inc. |
Piperazine compound and use thereof as a HCV polymerase inhibitor
|
MX2008014839A
(es)
|
2006-05-23 |
2008-12-05 |
Irm Llc |
Compuestos y composiciones en la forma de inhibidores de proteasa de activacion mediante canal.
|
AU2007261345B2
(en)
*
|
2006-06-19 |
2012-02-23 |
Onyx Therapeutics, Inc. |
Peptide epoxyketones for proteasome inhibition
|
WO2008008776A2
(en)
|
2006-07-11 |
2008-01-17 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
WO2008063727A2
(en)
*
|
2006-08-21 |
2008-05-29 |
United Therapeutics Corporation |
Combination therapy for treatment of viral infections
|
EP2057278A2
(en)
*
|
2006-08-28 |
2009-05-13 |
Vertex Pharmceuticals Incorporated |
Method for identifying protease inhibitors
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
NZ576780A
(en)
|
2006-11-15 |
2011-12-22 |
Virochem Pharma Inc |
Thiophene analogues for the treatment or prevention of flavivirus infections
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2673111A1
(en)
*
|
2006-12-07 |
2008-06-19 |
Schering Corporation |
Ph sensitive matrix formulation
|
WO2008079266A2
(en)
|
2006-12-21 |
2008-07-03 |
Wyeth |
Synthesis of pyrrolidine compounds
|
WO2008082484A1
(en)
|
2006-12-22 |
2008-07-10 |
Schering Corporation |
4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
|
CN101611002A
(zh)
|
2006-12-22 |
2009-12-23 |
先灵公司 |
用于治疗或预防hcv和相关病毒感染的4,5-环化吲哚衍生物
|
ATE543808T1
(de)
|
2006-12-22 |
2012-02-15 |
Schering Corp |
5,6-ring-annelierte indolderivate und ihre verwendung
|
AU2008212758B2
(en)
|
2007-02-08 |
2014-01-30 |
Medivir Ab |
Pyrimidine substituted macrocyclic HCV inhibitors
|
WO2008097676A1
(en)
*
|
2007-02-09 |
2008-08-14 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
GEP20125645B
(en)
*
|
2007-02-27 |
2012-09-25 |
Vertex Pharma |
Co-crystals and pharmaceutical compositions comprising the same
|
EP2134717A2
(en)
|
2007-02-27 |
2009-12-23 |
Vertex Pharmceuticals Incorporated |
Inhibitors of serine proteases
|
ATE525068T1
(de)
|
2007-02-28 |
2011-10-15 |
Conatus Pharmaceuticals Inc |
Verfahren zur behandlung von chronischer viraler hepatitis c mithilfe von ro 113-0830
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
EP2142215B1
(en)
|
2007-05-04 |
2012-03-07 |
Vertex Pharmceuticals Incorporated |
Combination therapy for the treatment of hcv infection
|
NZ582096A
(en)
|
2007-06-29 |
2012-05-25 |
Gilead Sciences Inc |
Antiviral compounds that inhibit hepatitis c virus (hcv)
|
SG182979A1
(en)
|
2007-06-29 |
2012-08-30 |
Gilead Sciences Inc |
Antiviral compounds
|
ES2447543T3
(es)
|
2007-08-29 |
2014-03-12 |
Merck Sharp & Dohme Corp. |
Derivados de indol sustituidos y métodos de utilización de los mismos
|
US8404845B2
(en)
|
2007-08-29 |
2013-03-26 |
Merck Sharp & Dohme Corp. |
2,3-substituted azaindole derivatives for treating viral infections
|
BRPI0816116A2
(pt)
|
2007-08-29 |
2015-03-03 |
Schering Corp |
Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
|
EP2185546B1
(en)
*
|
2007-08-30 |
2011-10-26 |
Vertex Pharmceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
KR20160086980A
(ko)
|
2007-10-04 |
2016-07-20 |
오닉스 세라퓨틱스, 인크. |
결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
|
US8377928B2
(en)
|
2007-11-16 |
2013-02-19 |
Merck Sharp & Dohme Corp. |
3-aminosulfonyl substituted indole derivatives and methods of use thereof
|
MX2010005356A
(es)
|
2007-11-16 |
2010-05-27 |
Schering Corp |
Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
TW200936131A
(en)
|
2008-02-04 |
2009-09-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2300491B1
(en)
|
2008-05-29 |
2016-01-06 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
EP2303893B1
(en)
|
2008-06-13 |
2016-12-07 |
Merck Sharp & Dohme Corp. |
Tricyclic indole derivatives
|
ES2458358T3
(es)
|
2008-07-02 |
2014-05-05 |
Idenix Pharmaceuticals, Inc. |
Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas
|
WO2010022121A1
(en)
|
2008-08-20 |
2010-02-25 |
Schering Corporation |
Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
AR072940A1
(es)
|
2008-08-20 |
2010-09-29 |
Schering Corp |
Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales
|
CA2734488A1
(en)
|
2008-08-20 |
2010-02-25 |
Southern Research Institute |
Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
CA2734489C
(en)
|
2008-08-20 |
2016-11-08 |
Southern Research Institute |
Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2010039801A2
(en)
|
2008-10-02 |
2010-04-08 |
The J. David Gladstone Institutes |
Methods of treating hepatitis c virus infection
|
BRPI0919668A2
(pt)
|
2008-10-21 |
2018-05-29 |
Onyx Therapeutics, Inc. |
terapia de combinação com epóxi-cetonas de peptídeo
|
AU2009322387A1
(en)
|
2008-12-03 |
2011-06-30 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of HCV NS5A
|
WO2010065674A1
(en)
|
2008-12-03 |
2010-06-10 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8914351B2
(en)
|
2008-12-16 |
2014-12-16 |
Clinton A. Krislov |
Method and system for secure automated document registration from social media networks
|
US8589372B2
(en)
|
2008-12-16 |
2013-11-19 |
Clinton A. Krislov |
Method and system for automated document registration with cloud computing
|
WO2010080389A1
(en)
*
|
2008-12-19 |
2010-07-15 |
Gilead Sciences, Inc. |
Hcv ns3 protease inhibitors
|
PT2376088T
(pt)
|
2008-12-23 |
2017-05-02 |
Gilead Pharmasset Llc |
Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
|
EP2376515A1
(en)
|
2008-12-23 |
2011-10-19 |
Pharmasset, Inc. |
Synthesis of purine nucleosides
|
NZ593649A
(en)
|
2008-12-23 |
2013-11-29 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
US8102720B2
(en)
*
|
2009-02-02 |
2012-01-24 |
Qualcomm Incorporated |
System and method of pulse generation
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス,インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤
|
JP2012520884A
(ja)
|
2009-03-18 |
2012-09-10 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー |
フラビウイルス科ウイルス感染症を治療する方法および組成物
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
CN102427726B
(zh)
|
2009-03-27 |
2014-10-08 |
普雷西迪奥制药公司 |
丙型肝炎的稠环抑制剂
|
WO2010117939A1
(en)
|
2009-04-06 |
2010-10-14 |
Schering Corporation |
Hcv inhibitor and therapeutic agent combinations
|
US9198907B2
(en)
|
2009-04-06 |
2015-12-01 |
Ptc Therapeutics, Inc. |
Combinations of a HCV inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
|
EP2417134B1
(en)
|
2009-04-08 |
2017-05-17 |
Idenix Pharmaceuticals LLC. |
Macrocyclic serine protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
JP2012528195A
(ja)
|
2009-05-29 |
2012-11-12 |
メルク・シャープ・アンド・ドーム・コーポレーション |
C型肝炎などの疾患を処置するための3つの結合アリール部分で構成された抗菌性化合物
|
WO2011017389A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
LT2477980T
(lt)
|
2009-09-15 |
2016-09-26 |
Taigen Biotechnology Co., Ltd. |
Hcv proteazės slopikliai
|
JP5919196B2
(ja)
|
2009-11-13 |
2016-05-18 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
転移抑制のためのペプチドエポキシケトンの使用
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
MX2012006026A
(es)
|
2009-11-25 |
2012-08-15 |
Vertex Pharma |
Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
|
EP2503881B1
(en)
|
2009-11-25 |
2015-05-13 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
RU2554087C2
(ru)
|
2009-12-18 |
2015-06-27 |
Айденикс Фармасьютикалз, Инк. |
5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
|
EP2516449A1
(en)
|
2009-12-22 |
2012-10-31 |
Cephalon, Inc. |
Proteasome inhibitors and processes for their preparation, purification and use
|
EP2516430B1
(en)
|
2009-12-22 |
2014-11-05 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
|
JP2013515746A
(ja)
|
2009-12-24 |
2013-05-09 |
ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド |
フラビウイルス感染症の治療又は予防のための類似体
|
SG182737A1
(en)
|
2010-01-27 |
2012-08-30 |
Pharma Ltd Ab |
Polyheterocyclic compounds highly potent as hcv inhibitors
|
EP2536410B1
(en)
|
2010-02-18 |
2015-09-23 |
Merck Sharp & Dohme Corp. |
Substituted pyrimidine derivatives and their use in treating viral infections
|
MA34133B1
(fr)
|
2010-03-01 |
2013-04-03 |
Onyx Therapeutics Inc |
Composes pour inhibiteurs de l'immunoproteasome
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
AR080676A1
(es)
|
2010-03-09 |
2012-05-02 |
Schering Corp |
Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
|
JP2013522377A
(ja)
|
2010-03-24 |
2013-06-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染を処置または予防するためのアナログ
|
WO2011119860A1
(en)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
TW201139438A
(en)
|
2010-03-24 |
2011-11-16 |
Vertex Pharma |
Analogues for the treatment or prevention of flavivirus infections
|
CN102869657A
(zh)
|
2010-03-24 |
2013-01-09 |
沃泰克斯药物股份有限公司 |
用于治疗或预防黄病毒感染的类似物
|
AP2012006535A0
(en)
|
2010-03-31 |
2012-10-31 |
Gilead Pharmasset Llc |
Stereoselective synthesis of phosphorous containing actives
|
BR112012024661A2
(pt)
|
2010-04-01 |
2015-09-15 |
Centre Nat Rech Scient |
composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
|
US8697646B2
(en)
|
2010-04-07 |
2014-04-15 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
US8877707B2
(en)
|
2010-05-24 |
2014-11-04 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of HCV NS5A
|
WO2011156545A1
(en)
|
2010-06-09 |
2011-12-15 |
Vertex Pharmaceuticals Incorporated |
Viral dynamic model for hcv combination therapy
|
EP2582717A2
(en)
|
2010-06-15 |
2013-04-24 |
Vertex Pharmaceuticals Incorporated |
Hcv ns5b polymerase mutants
|
AU2011276526A1
(en)
|
2010-06-28 |
2013-01-10 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of Flavivirus infections
|
WO2012006070A1
(en)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
WO2012006060A1
(en)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
AU2011286276A1
(en)
|
2010-07-26 |
2013-01-24 |
Merck Sharp & Dohme Corp. |
Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
|
WO2012020036A1
(en)
|
2010-08-13 |
2012-02-16 |
F. Hoffmann-La Roche Ag |
Hepatitis c virus inhibitors
|
JP2013534249A
(ja)
|
2010-08-17 |
2013-09-02 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス科ウイルス感染の処置または予防のための化合物および方法
|
US9254292B2
(en)
|
2010-09-29 |
2016-02-09 |
Merck Sharp & Dohme Corp. |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
US9011833B2
(en)
|
2010-10-08 |
2015-04-21 |
Novartis Ag |
Vitamin E formulations of sulfamide NS3 inhibitors
|
MX2013004906A
(es)
|
2010-11-01 |
2013-12-06 |
Genoscience Pharma |
Nuevos inhibidores especificos de la proteasa ns3 de hcv.
|
PT3042910T
(pt)
|
2010-11-30 |
2019-04-16 |
Gilead Pharmasset Llc |
2'-espiro-nucleósidos para utilização na terapia da hepatite c
|
WO2012109398A1
(en)
|
2011-02-10 |
2012-08-16 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
WO2012123298A1
(en)
|
2011-03-11 |
2012-09-20 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
EP2697242B1
(en)
|
2011-04-13 |
2018-10-03 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10501493B2
(en)
|
2011-05-27 |
2019-12-10 |
Rqx Pharmaceuticals, Inc. |
Broad spectrum antibiotics
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2012171332A1
(zh)
|
2011-06-16 |
2012-12-20 |
爱博新药研发(上海)有限公司 |
抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
|
BR112013032188A2
(pt)
|
2011-06-23 |
2016-12-20 |
Digna Biotech Sl |
composição, produto e método para tratar pacientes com hepatite c crônica
|
US20120328565A1
(en)
|
2011-06-24 |
2012-12-27 |
Brinkman John A |
Antiviral compounds
|
CN102807607B
(zh)
*
|
2011-07-22 |
2013-10-23 |
爱博新药研发(上海)有限公司 |
抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
|
WO2013016499A1
(en)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Methods for preparation of thiophene compounds
|
AR087344A1
(es)
|
2011-07-26 |
2014-03-19 |
Vertex Pharma |
Formas polimorficas del acido 5-(3,3-dimetil-but-1-inil)-3-[(trans-4-hidroxi-ciclohexil)-(trans-4-metil-ciclohexancarbonil)-amino]-tiofen-2-carboxilico y su uso en el tratamiento de la hepatitis c
|
WO2013033900A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
|
WO2013033899A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
|
WO2013033901A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
|
US9403863B2
(en)
|
2011-09-12 |
2016-08-02 |
Idenix Pharmaceuticals Llc |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
CN103906759A
(zh)
|
2011-09-12 |
2014-07-02 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
WO2013039876A1
(en)
|
2011-09-14 |
2013-03-21 |
Merck Sharp & Dohme Corp. |
Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
|
CN103917541B
(zh)
|
2011-10-10 |
2016-08-17 |
弗·哈夫曼-拉罗切有限公司 |
抗病毒化合物
|
EP2768838A1
(en)
|
2011-10-14 |
2014-08-27 |
IDENIX Pharmaceuticals, Inc. |
Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013072328A1
(en)
|
2011-11-14 |
2013-05-23 |
Sanofi |
Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
WO2013082476A1
(en)
|
2011-11-30 |
2013-06-06 |
Emory University |
Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
|
SG11201402899TA
(en)
|
2011-12-06 |
2014-07-30 |
Univ Leland Stanford Junior |
Methods and compositions for treating viral diseases
|
JP5923181B2
(ja)
|
2011-12-16 |
2016-05-24 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Hcvns5aの阻害剤
|
KR101687084B1
(ko)
|
2011-12-20 |
2016-12-15 |
리보사이언스 엘엘씨 |
Hcv rna 복제의 억제제로서 4'-아지도, 3'-플루오로 치환된 뉴클레오시드 유도체
|
SI2794629T1
(sl)
|
2011-12-20 |
2017-10-30 |
Riboscience Llc |
2'4'-difluoro-2'-metil substituirani nukleozidni derivati k0t zaviralci replikacije hcv-rna
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
EP2802574A4
(en)
|
2012-01-12 |
2015-06-24 |
Rfs Pharma Llc |
INHIBITORS OF HCV NS3 PROTEASE
|
US20130217644A1
(en)
|
2012-02-13 |
2013-08-22 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
|
WO2013123456A1
(en)
*
|
2012-02-16 |
2013-08-22 |
Rqx Pharmaceuticals, Inc. |
Linear peptide antibiotics
|
MX2014009799A
(es)
*
|
2012-02-24 |
2014-09-08 |
Hoffmann La Roche |
Compuestos antivirales.
|
EP2827876A4
(en)
|
2012-03-22 |
2015-10-28 |
Alios Biopharma Inc |
PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
|
US9109001B2
(en)
|
2012-05-22 |
2015-08-18 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphoramidate prodrugs for HCV infection
|
EP2852605B1
(en)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphate prodrugs for hcv infection
|
EA031301B1
(ru)
|
2012-05-22 |
2018-12-28 |
Иденикс Фармасьютикалз Ллс |
D-аминокислотные химические соединения для лечения заболеваний печени
|
US20140010783A1
(en)
|
2012-07-06 |
2014-01-09 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
US20140105921A1
(en)
|
2012-07-09 |
2014-04-17 |
Onyx Therapeutics, Inc. |
Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
|
WO2014053533A1
(en)
|
2012-10-05 |
2014-04-10 |
Sanofi |
Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
|
WO2014058801A1
(en)
|
2012-10-08 |
2014-04-17 |
Idenix Pharmaceuticals, Inc. |
2'-chloro nucleoside analogs for hcv infection
|
EP2909223B1
(en)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Dinucleotide compounds for hcv infection
|
EA025560B1
(ru)
|
2012-10-19 |
2017-01-30 |
Бристол-Майерс Сквибб Компани |
Ингибиторы вируса гепатита с
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
US10260089B2
(en)
|
2012-10-29 |
2019-04-16 |
The Research Foundation Of The State University Of New York |
Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
|
US9334279B2
(en)
|
2012-11-02 |
2016-05-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014070964A1
(en)
|
2012-11-02 |
2014-05-08 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2914614B1
(en)
|
2012-11-05 |
2017-08-16 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
WO2014078427A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
US20140140952A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Sp-Nucleoside Analog
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
EP2948440B1
(en)
|
2013-01-23 |
2017-04-12 |
F. Hoffmann-La Roche AG |
Antiviral triazole derivatives
|
WO2014134251A1
(en)
|
2013-02-28 |
2014-09-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
BR112015021429A2
(pt)
|
2013-03-05 |
2017-07-18 |
Hoffmann La Roche |
compostos antivirais
|
JP6342922B2
(ja)
|
2013-03-07 |
2018-06-13 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
C型肝炎ウイルス阻害剤
|
EP2981542B1
(en)
|
2013-04-01 |
2021-09-15 |
Idenix Pharmaceuticals LLC |
2',4'-fluoro nucleosides for the treatment of hcv
|
MA38678A1
(fr)
|
2013-05-16 |
2017-07-31 |
Riboscience Llc |
Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
|
US20180200280A1
(en)
|
2013-05-16 |
2018-07-19 |
Riboscience Llc |
4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
|
BR112015028764B1
(pt)
|
2013-05-16 |
2022-09-27 |
Riboscience Llc |
Derivados de nucleosídeo de 4-fluoro-2-metil substituídos como inibidores de replicação de rna do hcv
|
US10005779B2
(en)
|
2013-06-05 |
2018-06-26 |
Idenix Pharmaceuticals Llc |
1′,4′-thio nucleosides for the treatment of HCV
|
US20150037282A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
CN105636978A
(zh)
*
|
2013-08-14 |
2016-06-01 |
阿奇克斯制药公司 |
线性肽抗生素
|
CN105517540B
(zh)
|
2013-08-27 |
2019-08-23 |
吉利德制药有限责任公司 |
两种抗病毒化合物的复方制剂
|
EP3046924A1
(en)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
US10167298B2
(en)
|
2013-10-30 |
2019-01-01 |
Merck Sharp & Dohme Corp. |
Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
US20170198005A1
(en)
|
2013-11-27 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
EP3083654A1
(en)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or nucleosides for the treatment of hcv
|
EP2899207A1
(en)
|
2014-01-28 |
2015-07-29 |
Amikana.Biologics |
New method for testing HCV protease inhibition
|
WO2015134780A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
|
EP3114122A1
(en)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
WO2015134561A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
US10202411B2
(en)
|
2014-04-16 |
2019-02-12 |
Idenix Pharmaceuticals Llc |
3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
|
MX387476B
(es)
|
2015-11-20 |
2025-03-18 |
Rqx Pharmaceuticals Inc |
Antibióticos de amplio espectro macrocíclico.
|
EP3472130B1
(en)
|
2016-06-21 |
2022-02-16 |
Orion Ophthalmology LLC |
Aliphatic prolinamide derivatives
|
CA3025253A1
(en)
|
2016-06-21 |
2017-12-28 |
Orion Ophthalmology LLC |
Heterocyclic prolinamide derivatives
|
WO2017222914A1
(en)
|
2016-06-21 |
2017-12-28 |
Inception 4, Inc. |
Carbocyclic prolinamide derivatives
|
JP2019526563A
(ja)
*
|
2016-08-23 |
2019-09-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Htra1阻害剤としての新規ジフルオロケタミド誘導体
|
CN110709096B
(zh)
|
2017-05-05 |
2023-10-31 |
泽兰德制药公司 |
细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用
|
GB2563396B
(en)
*
|
2017-06-12 |
2020-09-23 |
Ustav Organicke Chemie A Biochemie Av Cr V V I |
Inhibitors of Rhomboid Intramembrane Proteases
|
JP7299897B2
(ja)
|
2017-09-21 |
2023-06-28 |
リボサイエンス リミティド ライアビリティ カンパニー |
Hcvのrna複製阻害剤としての4’-フルオロ-2’-メチル置換ヌクレオシド誘導体
|
EP3891508A1
(en)
|
2018-12-04 |
2021-10-13 |
Bristol-Myers Squibb Company |
Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
|
BR112021024010A2
(pt)
|
2019-05-28 |
2022-05-17 |
Hoffmann La Roche |
Antibióticos macrocíclicos de amplo espectro
|